Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $275

Benzinga · 1d ago
Guggenheim analyst Michael Schmitz maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $275.